ReviewCancers2026
Thermal Ablation of Hypervascular Liver Tumors After Selective Intra-Arterial Lipiodol Injection (SIALI): A Technical Narrative Review of Technique, Institutional Variations, and Published Evidence.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposePercutaneous thermal ablation of hypervascular liver tumors is limited by lesion conspicuity on conventional imaging, challenges with ablative margin assessment, and unequal global access to advanced technologies such as ablation confirmation software and radioembolization. This review describes the selective intra-arterial lipiodol injection (SIALI) technique, its technical variations across institutions, and summarizes published clinical outcomes for SIALI-guided thermal ablation of hepatic malignancies.
methodsA narrative review was conducted through structured searches of the PubMed, Embase, and Cochrane databases using terms including "selective intra-arterial lipiodol injection," "lipiodol-guided ablation," "SIALI," and "hepatic arterial lipiodol." Studies were selected based on relevance to SIALI technique, clinical outcomes, and comparator techniques, including hepatic arteriography with C-arm CT-guided ablation (hepACAGA) and ablation confirmation software. Full-text peer-reviewed articles were included; conference abstracts and letters were excluded. No formal PRISMA-compliant inclusion or exclusion criteria were applied, consistent with the narrative review format.
resultsSeven studies were identified, encompassing six retrospective cohort studies and one prospective randomized controlled trial, collectively comprising over 900 patients treated across institutions in Asia, Europe, and the United States. Across heterogeneous patient populations and technical approaches, SIALI-guided thermal ablation was associated with improved local tumor recurrence rates, local recurrence-free survival, and overall survival compared with conventional ultrasound- or CT-guided ablation alone in selected studies where comparator data were available, with favorable technical success rates in lesions otherwise occult on standard imaging.
conclusionSIALI appears to be a technically feasible and potentially useful adjunct technique that may improve lesion conspicuity and enable real-time ablative margin assessment in the treatment of hypervascular liver tumors, particularly in settings without access to ablation confirmation software. The available evidence is predominantly retrospective, and prospective validation is needed before broad conclusions regarding oncologic outcomes can be drawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.